Wisconsin pricing study finds 21% of sample drugs have non-volume-related pricing differences.
Executive Summary
WISCONSIN STUDY FINDS NON-VOLUME-RELATED PRICE DIFFERENCES FOR 21% OF DRUGS whose wholesale prices were examined across classes of trade, the Wisconsin Department of Agriculture, Trade & Consumer Protection stated in a study of prescription drug pricing released July 28. The study found that of the 76 drug products in the sample, 16 had pricing differences favoring institutional pharmacies over chain and independent pharmacies that "were not justified by volume purchases."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: